ELAVL1

Across TCGA pan-cancer cohorts, ELAVL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ELAVL1 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ELAVL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ELAVL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

HNSC, PDAC, and COAD are the cancer types where ELAVL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	IV	0.736	1.000	.008	18	view →
PDAC	DFS	Median	All	0.841	0.682	.004	13	view →
COAD	DFS	Median	All	1.000	0.889	.024	12	view →
UCEC	DFS	Median	All	0.933	1.000	.015	10	view →
CCRCC	OS	Median	All	0.949	0.851	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ELAVL1–HNSC (OS)

Open the HNSC breakdown →